|
1
|
Hacker UT, Wingenfeld L, Kofler DM,
Schuhmann NK, Lutz S, Herold T, King SB, Gerner FM, Perabo L,
Rabinowitz J, McCarty DM, Samulski RJ, Hallek M and Buning H:
Adeno-associated virus serotypes 1 to 5 mediated tumor cell
directed gene transfer and improvement of transduction efficiency.
J Gene Med. 7:1429–1438. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Li C, Bowles DE, van Dyke T and Samulski
RJ: Adeno-associated virus vectors: potential applications for
cancer gene therapy. Cancer Gene Ther. 12:913–925. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Daya S and Berns KI: Gene therapy using
adeno-associated virus vectors. Clin Microbiol Rev. 21:583–593.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Higano CS, Corman JM, Smith DC, Centeno
AS, Steidle CP, Gittleman M, Simons JW, Sacks N, Aimi J and Small
EJ: Phase 1/2 dose-escalation study of a GM-CSF-secreting,
allogeneic, cellular immunotherapy for metastatic
hormone-refractory prostate cancer. Cancer. 113:975–984. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mueller C and Flotte TR: Clinical gene
therapy using recombinant adeno-associated virus vectors. Gene
Ther. 15:858–863. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lee HS, Shin OK, Kim SJ, Lee WI, Jeong S,
Park K, Choe H and Lee H: Efficient gene expression by
self-complementary adeno-associated virus serotype 2 and 5 in
various human cancer cells. Oncol Rep. 18:611–616. 2007.PubMed/NCBI
|
|
7
|
Thorsen F, Afione S, Huszthy PC, Tysnes
BB, Svendsen A, Bjerkvig R, Kotin RM, Lonning PE and Hoover F:
Adeno-associated virus (AAV) serotypes 2, 4 and 5 display similar
transduction profiles and penetrate solid tumor tissue in models of
human glioma. J Gene Med. 8:1131–1140. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Blacklow NR, Hoggan MD, Sereno MS, Brandt
CD, Kim HW, Parrott RH and Chanock RM: A seroepidemiologic study of
adenovirus-associated virus infection in infants and children. Am J
Epidemiol. 94:359–366. 1971.PubMed/NCBI
|
|
9
|
Halbert CL, Miller AD, McNamara S, Emerson
J, Gibson RL, Ramsey B and Aitken ML: Prevalence of neutralizing
antibodies against adeno-associated virus (AAV) types 2, 5, and 6
in cystic fibrosis and normal populations: Implications for gene
therapy using AAV vectors. Hum Gene Ther. 17:440–447. 2006.
View Article : Google Scholar
|
|
10
|
Gao G, Vandenberghe LH, Alvira MR, Lu Y,
Calcedo R, Zhou X and Wilson JM: Clades of adeno-associated viruses
are widely disseminated in human tissues. J Virol. 78:6381–6388.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Nathwani AC, Gray JT, McIntosh J, Ng CY,
Zhou J, Spence Y, Cochrane M, Gray E, Tuddenham EG and Davidoff AM:
Safe and efficient transduction of the liver after peripheral vein
infusion of self-complementary AAV vector results in stable
therapeutic expression of human FIX in nonhuman primates. Blood.
109:1414–1421. 2007. View Article : Google Scholar
|
|
12
|
Berns KI and CRP: Parvoviridae. Field's
Virology. Knipe DM and PMH: Lippincott Williams & Wilkins;
Philadelphia: 2007
|
|
13
|
Cruet-Hennequart S, Maubant S, Luis J,
Gauduchon P, Staedel C and Dedhar S: α(v) integrins regulate cell
proliferation through integrin-linked kinase (ILK) in ovarian
cancer cells. Oncogene. 22:1688–1702. 2003.
|
|
14
|
Moschos SJ, Drogowski LM, Reppert SL and
Kirkwood JM: Integrins and cancer. Oncology (Williston Park).
21:13–20. 2007.
|
|
15
|
Wiksten JP, Lundin J, Nordling S, Lundin
M, Kokkola A, von Boguslawski K and Haglund C: Tenascin-C
expression correlates with prognosis in gastric cancer. Oncology.
64:245–250. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yamaguchi A, Ding K, Maehara M, Goi T and
Nakagawara G: Expression of nm23-H1 gene and Sialyl Lewis X antigen
in breast cancer. Oncology. 55:357–362. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Girod A, Ried M, Wobus C, Lahm H, Leike K,
Kleinschmidt J, Deleage G and Hallek M: Genetic capsid
modifications allow efficient re-targeting of adeno-associated
virus type 2. Nat Med. 5:1052–1056. 1999. View Article : Google Scholar
|
|
18
|
Grifman M, Trepel M, Speece P, Gilbert LB,
Arap W, Pasqualini R and Weitzman MD: Incorporation of
tumor-targeting peptides into recombinant adeno-associated virus
capsids. Mol Ther. 3:964–975. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
White AF, Mazur M, Sorscher EJ, Zinn KR
and Ponnazhagan S: Genetic modification of adeno-associated viral
vector type 2 capsid enhances gene transfer efficiency in polarized
human airway epithelial cells. Hum Gene Ther. 19:1407–1414. 2008.
View Article : Google Scholar
|
|
20
|
Work LM, Buning H, Hunt E, Nicklin SA,
Denby L, Britton N, Leike K, Odenthal M, Drebber U, Hallek M and
Baker AH: Vascular bed-targeted in vivo gene delivery using
tropism-modified adeno-associated viruses. Mol Ther. 13:683–693.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xie Q, Bu W, Bhatia S, Hare J,
Somasundaram T, Azzi A and Chapman MS: The atomic structure of
adeno-associated virus (AAV-2), a vector for human gene therapy.
Proc Natl Acad Sci USA. 99:10405–10410. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sali A and Blundell TL: Comparative
protein modelling by satisfaction of spatial restraints. J Mol
Biol. 234:779–815. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Brunger AT, Adams PD, Clore GM, DeLano WL,
Gros P, Grosse-Kunstleve RW, Jiang JS, Kuszewski J, Nilges M, Pannu
NS, Read RJ, Rice LM, Simonson T and Warren GL: Crystallography
& NMR system: A new software suite for macromolecular structure
determination. Acta Crystallogr D Biol Crystallogr. 54:905–921.
1998.
|
|
24
|
Chang JW, Lee H, Kim E, Lee Y, Chung SS
and Kim JH: Combined antitumor effects of an adenoviral cytosine
deaminase/thymidine kinase fusion gene in rat C6 glioma.
Neurosurgery. 47:931–938; discussion 938–939, 2000.
|
|
25
|
Wu P, Xiao W, Conlon T, Hughes J,
Agbandje-McKenna M, Ferkol T, Flotte T and Muzyczka N: Mutational
analysis of the adeno-associated virus type 2 (AAV2) capsid gene
and construction of AAV2 vectors with altered tropism. J Virol.
74:8635–8647. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Black ME, Newcomb TG, Wilson HM and Loeb
LA: Creation of drug-specific herpes simplex virus type 1 thymidine
kinase mutants for gene therapy. Proc Natl Acad Sci USA.
93:3525–3529. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Blumenthal M, Skelton D, Pepper KA, Jahn
T, Methangkool E and Kohn DB: Effective suicide gene therapy for
leukemia in a model of insertional oncogenesis in mice. Mol Ther.
15:183–192. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Grimm D, Kay MA and Kleinschmidt JA:
Helper virus-free, optically controllable, and two-plasmid-based
production of adeno-associated virus vectors of serotypes 1 to 6.
Mol Ther. 7:839–850. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Arnold GS, Sasser AK, Stachler MD and
Bartlett JS: Metabolic biotinylation provides a unique platform for
the purification and targeting of multiple AAV vector serotypes.
Mol Ther. 14:97–106. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Stachler MD and Bartlett JS: Mosaic
vectors comprised of modified AAV1 capsid proteins for efficient
vector purification and targeting to vascular endothelial cells.
Gene Ther. 13:926–931. 2006.PubMed/NCBI
|
|
31
|
White K, Buning H, Kritz A, Janicki H,
McVey J, Perabo L, Murphy G, Odenthal M, Work LM, Hallek M, Nicklin
SA and Baker AH: Engineering adeno-associated virus 2 vectors for
targeted gene delivery to atherosclerotic lesions. Gene Ther.
15:443–451. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Walters RW, Agbandje-McKenna M, Bowman VD,
Moninger TO, Olson NH, Seiler M, Chiorini JA, Baker TS and Zabner
J: Structure of adeno-associated virus serotype 5. J Virol.
78:3361–3371. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kim SJ, Nam YR, Shin O, Choi J, Lee B,
Chang JW, Kwon YK, Park K and Lee H: Treatment with hydroxyurea and
tyrphostin-1 significantly improves the transduction efficiency of
recombinant adeno-associated viruses in human cancer cells. Oncol
Rep. 14:1475–1479. 2005.PubMed/NCBI
|
|
34
|
Okada T, Uchibori R, Iwata-Okada M,
Takahashi M, Nomoto T, Nonaka-Sarukawa M, Ito T, Liu Y, Mizukami H,
Kume A, Kobayashi E and Ozawa K: A histone deacetylase inhibitor
enhances recombinant adeno-associated virus-mediated gene
expression in tumor cells. Mol Ther. 13:738–746. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Marks PA and Breslow R: Dimethyl sulfoxide
to vorinostat: development of this histone deacetylase inhibitor as
an anticancer drug. Nat Biotechnol. 25:84–90. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Petrs-Silva H, Dinculescu A, Li Q, Min SH,
Chiodo V, Pang JJ, Zhong L, Zolotukhin S, Srivastava A, Lewin AS
and Hauswirth WW: High-efficiency transduction of the mouse retina
by tyrosine-mutant AAV serotype vectors. Mol Ther. 17:463–471.
2009. View Article : Google Scholar : PubMed/NCBI
|
